Ideas to Action:

Independent research for global prosperity

Global Health Policy

CGD experts discuss such issues as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

X

Global Health Policy

Feed

 

What We’re Looking For in the IOM Report on PEPFAR

The Institute of Medicine (IOM) will soon release its much anticipated report evaluating the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR). Conducted at the request of Congress, the forthcoming report should follow up on points raised by a previous IOM report (2007), which provided a “short-term evaluation” of implementation after PEPFAR’s first three years, and which was soon followed by PEPFAR’s Congressional reauthorization in 2008. The new report is expected to broadly assess the cumulative performance of US HIV/AIDS programs, with two main tasks:

Failure to Launch: A Post-Mortem of GHI 1.0

Announced in May 2009 by President Obama, the Global Health Initiative (GHI) promised a new way for the United States to do business in global health. Fragmented U.S. programs would be united under a single banner; vertical structures would be dismantled in favor of an integrated approach; and narrow, disease-focused programs would transition toward a focus on broader health challenges, such as maternal health, child survival, and health systems’ strengthening.

The Spirit of GHI Lives!

The United States budget for 2011; red area is global health aid (Source: xkcd)

This is a joint post with Amanda Glassman.

The verdict is out (sort of): the proposed total global health appropriation for FY2012 will be $8.3 billion; $600m less than 2011 appropriations, $38.3m higher than the enacted amount in 2011 and $1.5 billion less than requested funding. More than $5.5 billion of this funding is appropriated to HIV/AIDS; $1.05 billion of which are contributions to the Global Fund. A further $2.6 billion is appropriated for USAID to fulfill a portfolio of responsibilities from nutrition to HIV/AIDS treatment and prevention. Some highlights:

Welcome Victoria Fan to CGD

Today we are excited to welcome Victoria Fan to CGD as a global health research fellow. Victoria is a health economist with extensive experience in the analysis and evaluation of health insurance, health financing,  and other public health policies, mainly in India as well as China and the U.S. (State of Vermont).

BMGF’s New President for Global Development: A Bonanza for Global Health?

Chris Elias, President & CEO at PATH, will step down from his current position and join the Bill & Melinda Gates Foundation (BMGF) as President for global DEVELOPMENT in February 2012. Yes, that’s global development, not global health. First reactions from many in global health lamented the "loss" of one of the field’s most accomplished and visible experts. But as we digested the details of the announcement and discussed its implications, we realized that the Foundation’s decision could be a bonanza for global health. Here are two reasons why:

Outing Global Development “Committers”: The Case of the UN Global Strategy on Women’s & Children’s Health

New York City’s annual high level UN bash is an occasion for grand, development-related announcements and commitments. This year’s meeting, which took place last week, focused on the Prevention and Control of Non-communicable diseases (NCDs), but I was particularly pleased to see follow up from one of last year’s big announcements--the Global Strategy for Women’s and Children’s Health. Following its launch at last year’s UN Leaders’ Summit for the Millennium Development Goals (MDGs) 2010, the strategy inspired over $40 billion in financial commitments, aiming “to save the lives of 16 million women and children by 2015.” This year, on September 20th, the Partnership for Maternal, Newborn and Child Health (PMNCH) released its one-year assessment of progress under this strategy.

Urgently Needed: PEPFAR’s Value for Money Plan

Looming budget cuts for FY2012 and recent reports about the decline in AIDS funding from the USG in FY2010 relative to FY2009 have triggered the classic Washington, D.C. tug-of-war; global health and development advocates are pushing to maintain funding levels, if not to increase them, and the U.S. Congress is looking for ways to increase oversight and management of taxpayer dollars. Advocates are rightly pointing out what would happen if we don’t have the money and Congress is rightly signaling that the party is over. What’s new? Nothing.

Pages

Tags